Search

Presents a letters to the editor about the secondary imatinib resistance associated with an aberrant bcr-abl fusion gene in the U.S.

Three patients suffering from chronic myelogenous leukaemia (CML), a 36-year-old woman in blast crisis, and a 64-year-old woman and a 60-year-old man in the chronic phase, participated in a clinical trial with STI571, a recently developed tyrosine kinase inhibitor with relative specificity for the BCR-ABL kinase. In all three patients, complete haematologic remission occurred within 2 months of the treatment being initiated. Subsequently the patient in blast crisis underwent allogeneic stem-cell transplantation. For the second patient, who had experienced many side effects with the standard treatment, STI571 led to a better quality of life. The third patient reached complete cytogenetic remission after 3 months of treatment. The development of STI571 is a major breakthrough in the treatment of CML. There are few side effects and the short-term results are excellent in specific patient categories. Further research is needed to establish the eventual role of STI571 in the treatment of CML.